Clinical Studies - Lactoferrin


1. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.

Mirabelli, C., Wotring, J. W., Zhang, C. J., McCarty, S. M., Fursmidt, R., Pretto, C. D., Qiao, Y., Zhang, Y., Frum, T., Kadambi, N. S., Amin, A. T., O’Meara, T. R., Spence, J. R., Huang, J., Alysandratos, K. D., Kotton, D. N., Handelman, S. K., Wobus, C. E., Weatherwax, K. J., . . . Sexton, J. Z. (2021). Proceedings of the National Academy of Sciences, 118(36), e2105815118. 

2. Ambulatory COVID-19 Patients Treated with Lactoferrin as a Supplementary Antiviral Agent: A Preliminary Study.                 

Rosa, L., Tripepi, G., Naldi, E., Aimati, M., Santangeli, S., Venditto, F., Caldarelli, M., & Valenti, P. (2021). Journal of Clinical Medicine, 10(18), 4276. 

3. The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study.

Algahtani, F. D., Elabbasy, M. T., Samak, M. A., Adeboye, A. A., Yusuf, R. A., & Ghoniem, M. E. (2021). Medicina, 57(8), 842.

4. Lactoferrin Against SARS-CoV-2: In Vitro and In Silico Evidences.

Campione, E., Lanna, C., Cosio, T., Rosa, L., Conte, M. P., Iacovelli, F., Romeo, A., Falconi, M., del Vecchio, C., Franchin, E., Lia, M. S., Minieri, M., Chiaramonte, C., Ciotti, M., Nuccetelli, M., Terrinoni, A., Iannuzzi, I., Coppeda, L., Magrini, A., . . . Bianchi, L. (2021). Frontiers in Pharmacology, 12.

5. The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor.

Hu, Y., Meng, X., Zhang, F., Xiang, Y., & Wang, J. (2021). Emerging Microbes & Infections, 10(1), 317–330.

6. Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro.

Salaris, C., Scarpa, M., Elli, M., Bertolini, A., Guglielmetti, S., Pregliasco, F., Blandizzi, C., Brun, P., & Castagliuolo, I. (2021). Nutrients, 13(2), 328.

7. Lactoferrin as potential supplementary nutraceutical agent in COVID-19 patients: in vitro and in vivo preliminary evidences.

Campione, E., Lanna, C., Cosio, T., Rosa, L., Conte, M. P., Iacovelli, F., Romeo, A., Falconi, M., del Vecchio, C., Franchin, E., Lia, M. S., Minieri, M., Chiaramonte, C., Ciotti, M., Nuccetelli, M., Terrinoni, A., Magrini, A., Bernardini, S., Andreoni, M., . . . Bianchi, L. (2020a). Lactoferrin as Potential Supplementary Nutraceutical Agent in COVID-19 Patients: In Vitro and in Vivo Preliminary Evidences. Published.

8. The Potential of Antimicrobial Peptides as an Antiviral Therapy against COVID-19.

Elnagdy, S., & AlKhazindar, M. (2020). ACS Pharmacology & Translational Science, 3(4), 780–782.

9. Lactoferrin as an immunomodulatory and iron-binding agent: Possible clinical implication in COVID-19.

Morsi, D., Ibrahim, H., Mohamed, A., Osman, G., & Salem, M. (2020). International Journal of Cancer and Biomedical Research 

10. Liposomal Lactoferrin as Potential Preventative and Cure for COVID-19.

Serrano, G., Kochergina, I., Albors, A., Diaz, E., Oroval, M., Hueso, G., & Serrano, J. M. (2020). International Journal of Research in Health Sciences, 8(1), 08–15.

11. Lactoferrin as potential preventative and adjunct treatment for COVID-19.
Chang, R., Ng, T. B., & Sun, W. Z. (2020). International Journal of Antimicrobial Agents, 56(3), 106118. 

12. Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans.
Lang, J., Yang, N., Deng, J., Liu, K., Yang, P., Zhang, G., & Jiang, C. (2011). PLoS ONE, 6(8), e23710.

13. Antiviral Properties of Lactoferrin—A Natural Immunity Molecule.
Berlutti, F., Pantanella, F., Natalizi, T., Frioni, A., Paesano, R., Polimeni, A., & Valenti, P. (2011). Molecules, 16(8), 6992–7018.

14. Therapeutic Effects of Lactoferrin in Ocular Diseases: From Dry Eye Disease to Infections.
Vagge, A., Senni, C., Bernabei, F., Pellegrini, M., Scorcia, V., Traverso, C. E., & Giannaccare, G. (2020). International Journal of Molecular Sciences, 21(18), 6668.

15. The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosan-nanocarriers on osteoarthritis.
Samarasinghe, R. M., Kanwar, R. K., & Kanwar, J. R. (2014). Biomaterials, 35(26), 7522–7534.

16. Oral Administration of Lactoferrin Inhibits Inflammation and Nociception in Rat Adjuvant-Induced Arthritis.
HAYASHIDA, K. I., KANEKO, T., TAKEUCHI, T., SHIMIZU, H., ANDO, K., & HARADA, E. (2004). Journal of Veterinary Medical Science, 66(2), 149–154.

17. Efficacy and tolerability of oral lactoferrin supplementation in mild to moderate acne vulgaris: an exploratory study.
Mueller, E. A., Trapp, S., Frentzel, A., Kirch, W., & Brantl, V. (2011). Current Medical Research and Opinion, 27(4), 793–797.

18. Effects of a Bovine Lactoferrin Formulation from Cow’s Milk on Menstrual Distress in Volunteers: A Randomized, Crossover Study.
Ueno, H., Yoshise, R., Sugino, T., Kajimoto, O., & Kobayashi, T. (2016). International Journal of Molecular Sciences, 17(6), 845.

19. Effect of Lactoferrin Supplementation on Iron Deficiency Anemia in Primary School Children.
El-Khawaga, A., & Abdelmaksoud, H. (2019). International Journal of Medical Arts

20. Efficacy of Lactoferrin Oral Administration in the Treatment of Anemia and Anemia of Inflammation in Pregnant and Non-pregnant Women: An Interventional Study.
Lepanto, M. S., Rosa, L., Cutone, A., Conte, M. P., Paesano, R., & Valenti, P. (2018). Frontiers in Immunology, 9.

Click here to learn more about US Clinicals® StrongImmune Lactoferrin™.